Typewriter emerged from stealth with a $56M Series A to commercialize retrotransposon-based whole-gene insertion, targeting in vivo CAR-T and genetic liver disease. Non-human primate data arrives late 2026.
AeroVironment’s $464.8 million E-HEL award moves the 30 kW LOCUST X3 laser from prototype to production — the first directed-energy system in US military history to cross that line, and a signal that laser C-UAS economics have finally won.
Gridsight raised a $26M Series B led by Insight Partners to scale AI grid-capacity software. The platform doubled household solar export and unlocked 600+ MW on an existing network.
Crusoe closed a $3B round at a $30B valuation, anchored by a $13B Jane Street GPU contract. The energy-first neocloud model just got repriced.
Space domain awareness is becoming the traffic control layer of the commercial orbit economy. Inside the 2026 funding wave, the shift to AI threat detection, and who owns the catalog.
Biotech & Health The First RAS-Targeted Pancreatic Cancer Drug Just Changed the Math RASONQUE (daraxonrasib) is the first approved drug to hit RAS directly, the driver behind 90% of pancreatic tumours. In RASolute 302 it doubled median survival. Then came the $39,800-a-month list price. We assess
RASONQUE (daraxonrasib) is the first approved drug to hit RAS directly, the driver behind 90% of pancreatic tumours. In RASolute 302 it doubled median survival. Then came the $39,800-a-month list price. We assess the clinical event against the commercial bet.
Humanoids crossed from demo to deployment, but the evidence base is mostly vendor-authored. Agility's SPAC is about to price the gap for the first time.
Crusoe closed a $3B round at a $30B valuation, anchored by a $13B Jane Street GPU contract. The energy-first neocloud model just got repriced.
PwC's Global Data Centre Outlook models $31.6 trillion of AI infrastructure capex through 2050. The bulk buys hardware that refreshes every four to six years, so the build-out never ends. Power access and chip trade flows, not capital, decide which regions capture it.
Two-thirds of all AI compute in 2026 goes to running models, not building them. The crossover happened quietly, and it changes what gets funded.
The chips that run AI are now being designed by AI. Agentic EDA tools are reshaping how semiconductors are built, from a $74M startup to the giants of the industry. A look at who wins.
AeroVironment’s $464.8 million E-HEL award moves the 30 kW LOCUST X3 laser from prototype to production — the first directed-energy system in US military history to cross that line, and a signal that laser C-UAS economics have finally won.
Humanoids crossed from demo to deployment, but the evidence base is mostly vendor-authored. Agility's SPAC is about to price the gap for the first time.
The U.S. military just placed its first large-scale production order for ground-vehicle autonomy. A $92M ROGUE-Fires Block 2 award turns a venture bet into a program of record — and reveals how defence-robotics exits now work.
Global counter-drone spending passed $53 billion in 2026 as two $500 million Pentagon contracts split the market between Perennial Autonomy’s $15,000 kinetic interceptors and AeroVironment’s high-energy lasers.
Typewriter emerged from stealth with a $56M Series A to commercialize retrotransposon-based whole-gene insertion, targeting in vivo CAR-T and genetic liver disease. Non-human primate data arrives late 2026.
RASONQUE (daraxonrasib) is the first approved drug to hit RAS directly, the driver behind 90% of pancreatic tumours. In RASolute 302 it doubled median survival. Then came the $39,800-a-month list price. We assess the clinical event against the commercial bet.
Cell-free biomanufacturing crossed from lab to industrial pilot in 18 months. Four companies carry the commercial thesis.
Generate:Biomedicines has moved its AI-engineered anti-TSLP antibody GB-0895 into two global Phase 3 trials in severe asthma. 1,600 patients, six-month dosing, $457.4M in cash. The readout will revalue the entire generative-biology cohort.
Get daily updates on the technologies and investment opportunities shaping the next decade — from AI infrastructure and autonomous systems to biotech, space, and defence. Curated analysis, no noise.
